Published in Hepatology on August 25, 2014
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology (2015) 1.30
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. J Clin Transl Hepatol (2015) 1.03
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol (2015) 0.99
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol (2016) 0.85
Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver (2016) 0.84
Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol (2015) 0.82
Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation. Int J Mol Sci (2016) 0.82
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci (2016) 0.82
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci (2016) 0.81
The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges. Int J Mol Sci (2016) 0.81
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci (2016) 0.81
Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. Drug Des Devel Ther (2015) 0.81
Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review. Int J Mol Sci (2016) 0.80
Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. Int J Mol Sci (2016) 0.80
Herbal medicine-related hepatotoxicity. World J Hepatol (2015) 0.80
Metabolomic Study on Idiosyncratic Liver Injury Induced by Different Extracts of Polygonum multiflorum in Rats Integrated with Pattern Recognition and Enriched Pathways Analysis. Front Pharmacol (2016) 0.80
Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013. Drug Test Anal (2015) 0.79
Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regul Toxicol Pharmacol (2015) 0.78
The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol (2016) 0.78
Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. Gastroenterology (2015) 0.78
Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther (2015) 0.77
Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep (2015) 0.76
Herbal and Dietary Supplement-Induced Liver Injury. Clin Liver Dis (2016) 0.75
Drug-Induced Liver Injury Associated with Complementary and Alternative Medicines. Case Rep Gastroenterol (2016) 0.75
Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature. Case Reports Hepatol (2015) 0.75
Severe Cholestasis and Bile Acid Nephropathy From Anabolic Steroids Successfully Treated With Plasmapheresis. ACG Case Rep J (2016) 0.75
Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study. Drug Saf (2016) 0.75
Drug-induced liver injury: Do we know everything? World J Hepatol (2017) 0.75
Drug-Induced Liver Injury: Advances in Mechanistic Understanding that will Inform Risk Management. Clin Pharmacol Ther (2016) 0.75
Supplements and Hepatotoxicity. Gastroenterol Hepatol (N Y) (2015) 0.75
Research Advances on Hepatotoxicity of Herbal Medicines in China. Biomed Res Int (2016) 0.75
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci (2016) 0.75
Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol (2017) 0.75
Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products. Front Pharmacol (2015) 0.75
"Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci (2017) 0.75
Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut (2017) 0.75
Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol (2017) 0.75
Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am J Gastroenterol (2017) 0.75
Supplement-Induced Liver Injury. Gastroenterol Hepatol (N Y) (2017) 0.75
Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 35.46
Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med (1993) 28.86
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol (2004) 6.90
Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA (2008) 5.72
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report (2009) 5.44
Dietary supplement use in the United States, 2003-2006. J Nutr (2010) 4.72
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol (2012) 2.75
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology (2013) 2.72
Factors associated with dietary supplement use among healthy adults of five ethnicities: the Multiethnic Cohort Study. Am J Epidemiol (2003) 2.30
Why US adults use dietary supplements. JAMA Intern Med (2013) 2.29
Dietary supplement use among infants, children, and adolescents in the United States, 1999-2002. Arch Pediatr Adolesc Med (2007) 2.16
Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol (2008) 2.07
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr J (2007) 1.77
Use of dietary supplements in the United States, 1988-94. Vital Health Stat 11 (1999) 1.55
Microbial contamination of medicinal plants--a review. Planta Med (2002) 1.24
Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis (1981) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf (2000) 1.04
Screening methods for drugs and heavy metals in Chinese patent medicines. Bull Environ Contam Toxicol (2000) 0.95
Mycotoxins in root extracts of American and Asian ginseng bind estrogen receptors alpha and beta. Exp Biol Med (Maywood) (2004) 0.94
A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown. Leg Med (Tokyo) (2007) 0.92
Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol (2002) 0.87
Heavy metals in some Chinese herbal plants. Biol Trace Elem Res (1993) 0.85
Side effects of anabolic androgenic steroids: pathological findings and structure-activity relationships. Handb Exp Pharmacol (2010) 0.85
Use and safety perceptions regarding herbal supplements: a study of older persons in southeast Idaho. J Nutr Elder (2009) 0.83
Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J Clin Gastroenterol (2009) 0.83
Hepatotoxicity associated with the dietary supplement N.O.-XPLODE. Ann Intern Med (2013) 0.81
Complementary and alternative therapies in prostate cancer. Semin Oncol (2002) 0.81
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology (2014) 4.04
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr (2015) 1.98
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Therapy for hepatitis C--the costs of success. N Engl J Med (2014) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93